Visiongain Report Looks at Opportunities within the $47bn Asthma & COPD Market

Visiongain Report Looks at Opportunities within the $47bn Asthma & COPD Market

PR Newswire

LONDON, January 24, 2019

LONDON, January 24, 2019 /PRNewswire/ --

Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029 

Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast 

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $47bn by 2029.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 160-page report you will receive 86 charts- all unavailable elsewhere.

The 160-page report provides clear detailed insight into the Top 20 asthma & COPD companies. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Global Asthma & COPD Therapies Market forecasts from 2019-2029

• Profiles of the leading 20 asthma & COPD companies:
• Aerocrine (Circassia)
• ALK-Abello A/S
• Amphastar Pharmaceuticals, Inc.
• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Cipla
• GlaxoSmithKline
• Lallemand Pharma International
• Merck
• MundiPharma
• Novartis
• Pulmatrix
• Roche
• Sanofi/Regeneron
• Sunovion
• Teva
• Theravance Biopharma|Mylan Inc.
• Vectura Group plc
• Verona Pharma plc

• The content of each profile differs, depending on the organization. In general, a profile gives the following information:
• An overview and analysis of the company
• A portfolio of the company's marketed product and product pipeline
• Financial Information
• Revenue forecast from 2019-2029
• Recent developments
• Future Outlook

• This report discusses factors that drive and restrain the asthma and COPD market.

Visiongain's study is intended for anyone requiring commercial analyses for the top 20 asthma & COPD therapies companies. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029: Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/pharma-leader-series-top-20-asthma-copd-companies-2019-2029/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.com to discuss any customized research needs you may have.

Aerocrine (Circassia)
ALK-Abello A/S
American College of Chest Physicians (ACCP)
Amphastar Pharmaceuticals, Inc.
AstraZeneca
Boehringer Ingelheim
Chiesi Farmaceutici
Ciba-Geigy
Cipla
Committee for Medicinal Products for Human Use (CHMP)
Dainippon Sumitomo Pharma America, Inc.
Dermira Inc.
European Medicines Agency (EMA)
European Respiratory Society (ERS)
GlaxoSmithKline (GSK)
Glenmark
Hikma
Innovata plc
Innoviva, Inc.
Japanese Ministry of Health, Labour and Welfare
Lallemand Pharma International
Medicines and Healthcare products Regulatory Agency (MHRA)
Merck
Monitored Therapeutics, Inc. (MTI)
MundiPharma
Mylan
National Institute for Health and Care Excellence (NICE)
Novartis
Pulmatrix
Regeneron
Roche
Sandoz
Sanofi
Sepracor Inc.
Sorrento
Sunovion
Teva
Theravance Biopharma|Mylan Inc.
Torii
Vectura Group plc
Verona Pharma plc

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com


Voltar noticias em Inglês